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Inhibitors of PLA2Phospholipases A2 (PLA2) catalyse the cleavage of fatty acids esteriﬁed at the sn-2 position of glyceropho-
spholipids. In acute lung injury-acute respiratory distress syndrome (ALI-ARDS) several distinct isoenzymes
appear in lung cells and ﬂuid. Some are capable to trigger molecular events leading to enhanced
inﬂammation and lung damage and others have a role in lung surfactant recycling preserving lung function:
Secreted forms (groups sPLA2-IIA, -V, -X) can directly hydrolyze surfactant phospholipids. Cytosolic PLA2
(cPLA2-IVA) requiring Ca2+ has a preference for arachidonate, the precursor of eicosanoids which participate
in the inﬂammatory response in the lung. Ca2+-independent intracellular PLA2s (iPLA2) take part in
surfactant phospholipids turnover within alveolar cells. Acidic Ca2+-independent PLA2 (aiPLA2), of lysosomal
origin, has additionally antioxidant properties, (peroxiredoxin VI activity), and participates in the formation
of dipalmitoyl-phosphatidylcholine in lung surfactant. PAF-AH degrades PAF, a potent mediator of
inﬂammation, and oxidatively fragmented phospholipids but also leads to toxic metabolites. Therefore, the
regulation of PLA2 isoforms could be a valuable approach for ARDS treatment.© 2009 Elsevier B.V. All rights reserved.idonyl triﬂuoromethylketone;
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Acute lung injury (ALI) and its severe form Acute Respiratory
Distress Syndrome (ARDS) is a life threatening situation with high
mortality rates. The pathophysiology of ALI/ARDS is associated with
an excessive and protracted inﬂammation, characterized by increased
vascular permeability, extravasation of plasma and leucocytes inﬁltra-
tion. It is often systemic, resulting in multi-organ dysfunction and
death. Since inﬂammation is thought to contribute to the pathogen-
esis of ALI/ARDS it is rational to explore modulating therapies in this
context. Thus, the investigation and clariﬁcation of underlying
mechanisms of the inﬂammatory processes may contribute to such
therapeutic approaches [1,2].
Clinically, ALI/ARDS is characterized by an abrupt onset of hypo-
xemic respiratory failure, pulmonary oedema and lung inﬁltrates.
ALI/ARDS resulting from direct lung insults (e.g. aspiration, inhala-
tion, or lung infection) is termed pulmonary, primary or direct ARDS
and when the initial cause is systemic (e.g. sepsis or traumatic shock)
it is termed extrapulmonary, secondary or indirect ARDS. In addi-
tion to this distinction, a classiﬁcation into early, late, persistent and
chronic phases is also used. The early ARDS/ALI (b2 days from the
initiation) is characterized by lung ﬂooding with proteinaceous ﬂuid.
Prominent features that can be visualized by electron microscopy
are: swelling of endothelial cells, widening of intercellular junctions,
increased numbers of pinocytotic vesicles, and disruption of the
basement membrane. Within this period of time, pulmonary oedema
is most pronounced. Over the ensuing days (2–7 days), in late phase,
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During the persistent phase of ALI/ARDS interstitial inﬂammation is
the main characteristic, while chronic phase is dominated by exten-
sive pulmonary ﬁbrosis [3–6]. Patients of all ages have the proba-
bility to develop ALI/ARDS, however, data indicate that genetic
predisposition plays a role [7–9]. In the development of the syn-
drome, various inﬂammatory cells such as polymorphonuclear neutro-
phils, alveolar macrophages and platelets participate [for review see
ref. 10].
ALI/ARDS is associated with lung surfactant disorders which can
be observed soon after the initial injurious event and leads to
increased surface tension, alveolar collapse, loss of liquid balance in
the lung and deﬁciency of immune host defence [11,12]. Surfactant is a
lipoprotein complex with essential role in reducing surface tension at
the air–liquid interface of lung epithelia; in addition, it is a critical
component in lung host defence. It is mainly composed by phos-
pholipids and especially dipalmitoyl-phosphatidylcholine and phos-
phatidylglycerol, while approximately a 10% is comprised of speciﬁc
proteins. Hydrophilic surfactant proteins SP-A and SP-D belong to the
collectin family and they regulate innate immune functions in inﬂam-
matory cells like macrophages. They also modulate the adaptive
immune response by interacting with antigen-presenting and T-cells,
thereby linking innate and adaptive immunity. The hydrophobic sur-
factant proteins SP-B and SP-C contribute to the surface properties of
pulmonary surfactant [13,14].
Surfactant can be readily hydrolysed by phospholipases A2 (PLA2),
which are produced during inﬂammation. The produced lyso-
phospholipids and eicosanoids have been implicated in the pathogen-
esis of acute lung injury [15–19].
2. Phospholipases A2 (PLA2s)
PLA2s are esterases that catalyse the hydrolysis of acyl groups at
the sn-2 position of glycerophospholipids (PL) and produce free fatty
acids and lyso-PL by an interfacial activation catalytic mechanism. To
date, at least 26 genes that encode various types of proteins with PLA2
activity have been identiﬁed in human. These enzymes can be
classiﬁed into groups according to their biochemical characteristics,
properties and localisation [20–23] (Table 1).
PLA2s are expressed and released by human inﬂammatory cells
such as neutrophils, eosinophils, T-cells, monocytes, macrophages
and mast cells [24]. Several studies have shown that various types
of phospholipases A2 can be implicated in the pathogenesis of ALI/
ARDS through the production of potent lipid mediators [15,25]. In
particular, the liberated arachidonic acid (AA) is the precursor of
eicosanoids, signalling molecules formed by cycloxygenases, lipox-
ygenases or endoperoxidases. These bind to speciﬁc G-protein
coupled receptors and exert complex control over inﬂammation or
immunity. Lyso-PLs are precursors for lysophosphatidic acid (LPA)
and platelet activating factor (PAF), which are associated with
cardiovascular homeostasis, inﬂammation and immunity. Lyso-PLs
modulate the expression of speciﬁc pro-inﬂammatory genes by
mobilising the phagocyte receptor G2A [26]. Due to their tensioac-
tive properties they can deteriorate the structure of cell mem-
branes. On the contrary, others PLA2s participate in surfactant
biosynthesis through phospholipid remodelling, contributing to lung
integrity [27].
PLA2s can disturb pulmonary function either directly, by hydro-
lyzing lung surfactant phospholipids or indirectly, through the
production of biologically active molecules. This leads to increased
alveolar–capillary barrier permeability and lung oedema formation
which characterize ALI/ARDS [28,29].
Taking into account the complexity of this superfamily of enzymes,
in this work we are going to focus on the function of various PLA2
isotypes in lung parenchyma and their implication in the develop-
ment of ALI/ARDS.2.1. Secretory PLA2s (sPLA2s)
sPLA2s are low molecular weight secretory proteins (14–57 kDa)
which usually contain 5–8 disulﬁde bonds (protein data bank number
1DB4) [30]. They possess a histidine in their active site, require mM
levels of Ca2+ and show preference for anionic phospholipids as
substrates, such as phosphatidylglycerol, a major component of sur-
factant phospholipids. Ten human genes encode the active secreted
PLA2 enzymes [31].
Total lung extracts express sPLA2-IB, -IIA, -V, and -X. The prominent
implication of sPLA2-IB and sPLA2-IIA in inﬂammation and ALI/ARDS
has been established long ago in experimental models [32–34].
However, a role for sPLA2-X and -V cannot be excluded, given that,
these isoforms appear uniquely expressed in airway epithelium and
can effectively hydrolyze lung surfactant [35].
2.1.1. sPLA2-IB
sPLA2-IB, (pancreatic phospholipase A2, gene PLA2G1B), has a
widespread tissue distribution, including lung [36]. It is a low
molecular weight (14 kDa), Ca2+-dependent enzyme, activated by
proteolytic cleavage of a cytosolic inactive propeptide [37]. It
modulates inﬂammatory, immune responses and chemotaxis in
human neutrophils through leukotriene B4 production [38]. Apart
from its direct lipolytic activity it also acts through binding to the
membrane receptor for secretory PLA2s (PLA2R), (Scheme 1–1),
[39,40].
sPLA2-IB has been detected in serum of patients with acute lung
injury but not in healthy controls. It can be used as a diagnostic and
prognostic marker since the presence of the sPLA2-IB propeptide
showed a 100% sensitivity for patients with ALI and 93% speciﬁcity for
future development of ALI [41]. The enzyme has also been implicated
in complications of severe acute pancreatitis [42,43], a recognized risk
factor for ALI/ARDS.
A cross-talk between sPLA2-IB and sPLA2-IIA has been reported.
Interaction of the mature sPLA2-IB with its speciﬁc receptor caused an
elevation in prostaglandin E2 synthesis, PLA2-II mRNA levels as well as
in an increase in PLA2-II secretion in rat messangial cells. Both PLA2-II
expression and PGE2 synthesis were completely suppressed after
pretreatment of the cells with actinomycin D and cycloheximide,
inhibitors of protein synthesis, or dexamethasone, a potent anti-
inﬂammatory corticosteroid [44].
2.1.2. sPLA2-IIA
sPLA2-IIA (gene PLA2G2A) is themost studied isoform. It is a Ca2+-
dependent enzyme with optimum pH: 8.0–10.0. The amino acid
sequence of the human protein consists of 124 amino acids, contains
structural features common to all known phospholipases A2, and has a
half-cystine pattern that is characteristic of the snake venom group II
enzymes [45].
sPLA2-IIA is present in platelets and is highly expressed in alveolar
macrophages of a model of ALI induced by LPS and TNF-alpha [46]
(Scheme 1–2). It is stored in the secretory granules of cells, and also
expressed in various human tissues including lung [47]. It plays a role
in normal cellular function such as lipid remodelling for cell
membrane homeostasis, antimicrobial activity, anticoagulation and
cell adhesion; in addition, it has been implicated in inﬂammatory
diseases, septic shock and adult respiratory distress syndrome [for
review see ref. 48]. The bactericidal – antimicrobial activity of sPLA2-
IIA is exerted against gram-positive and -negative bacteria [49,50].
The action against gram-negative bacteria appears to require the
presence of other agents, such as bactericidal/permeability-increasing
protein, whereas this requirement is not necessary against gram-
positive ones [51]. In addition, sPLA2-IIA is regarded as an acute phase
protein [52,53].
During the last years, the involvement of secretory phospholipases
A2 in ARDS and sepsis has been widely recognized [54]. In the
Table 1
Classiﬁcation and characteristics of human PLA2s.
Types Protein name Common designation Names of the
origin genes
Length (aa) Calcium requirement Subcellular localization
Cytosolic
PLA2s (cPLA2s)
Phospholipase A2 group IVA cPLA2-IVA or cPLA2α PLA2G4A 749 Yes (only for
translocation to
membrane vesicles)
Cytoplasmic vesicles;
Nucleus
Phospholipase A2 group IVB
(isoforms β1/β2/β4)
cPLA2β1/cPLA2β2/
cPLA2β4
PLA2G4B 781/661/482 Yes Cytosol
Phospholipase A2 group IVB
(isoform β3)
cPLA2β3 PLA2G4B 656 Yes Cytosol; Mitochondria;
early endosomes
Phospholipase A2 group IVC cPLA2-IVC or cPLA2γ PLA2G4C 541 No Endoplasmic reticulum;
mitochondria
Phospholipase A2 group IVD cPLA2-IVD or cPLA2δ PLA2G4D 818 Yes (for enzymic activity
and translocation
to membrane vesicles)
Cytosol; Cytoplasmic
vesicle membrane;
peripheral membrane
protein; cytoplasmic side
Phospholipase A2 group IVE cPLA2-IVE cPLA2ɛ PLA2G4E 838 Yes (for enzymic activity
and translocation to
membrane vesicles)
Cytosol; Lysosome
membrane; peripheral
membrane protein;
cytoplasmic side
Phospholipase A2 group IVF cPLA2-IVF or cPLA2ζ PLA2G4F 849 Yes (for enzymic activity
and translocation to
membrane vesicles)
Cytosol; lysosome
membrane; peripheral
membrane protein;
cytoplasmic side
Secretory
PLA2s (sPLA2s)
Phospholipase A2 group IB sPLA2-IB PLA2G1B 148 Yes Secreted
Phospholipase A2 group IIA sPLA2-IIA PLA2G2A 144 Yes Secreted; membrane;
peripheral membrane;
secretory granules
Phospholipase A2 group IID sPLA2-IID PLA2G2D 145 Yes Secreted
Phospholipase A2 group IIE sPLA2-IIE PLA2G2E 142 Yes Secreted
Phospholipase A2 group IIF sPLA2-IIF PLA2G2F 168 Yes Secreted
Phospholipase A2 group III sPLA2-III PLA2G3 509 Yes Secreted
Phospholipase A2 group V sPLA2-V PLA2G5 138 Yes Secreted; Golgi apparatus;
nuclear envelope; plasma
membrane
Phospholipase A2 group X sPLA2-X PLA2G10 155 Yes Secreted
Phospholipase A2 group XIIA sPLA2-XIIA PLA2G12A 189 Yes Secreted; cytoplasm
Phospholipase A2 group XIIB
(or XIII)
sPLA2-XIIB
(or sPLA2-XIII)
PLA2G12B 194 Yes Secreted
Intracellular
calcium-independent
PLA2s (iPLA2s)
Ca2+-independent phospholipase
A2 group VIA (multiple short
isoforms from transcript variants)
iPLA2-VIA or iPLA2-β PLA2G6 752 No Cytosol
Ca2+-independent phospholipase
A2 group VIB, isoform LH-iPLA2
(long isoform)
iPLA2-VIB or iPLA2-γ PLA2G6 806 No Endoplasmic, peroxisomal
and mitochondrial
membranes
Phospholipase A2 group VIC or
neuropathy target esterase or
Patatin-like phospholipase
domain-containing
iPLA2-VIC or iPLA2-δ PNPLA6 1366 No Endoplasmic reticulum
membrane; single-pass
type I membrane protein;
cytoplasmic side
Phospholipase A2 group VID or
Patatin-like phospholipase
domain-containing protein 3 or
Acylglycerol O-acyltransferase
or Adiponutrin
iPLA2-VID or iPLA2ɛ PNPLA3 481 No Membrane; single-pass
type II membrane protein
Phospholipase A2 group VIE or
Patatin-like phospholipase
domain-containing protein 2 or
Adipose triglyceride lipase or
Desnutrin or TTS2
iPLA2-VIE or iPLA2ζ PNPLA2 504 No Lipid droplet membrane;
single-pass type II
membrane protein;
cell membrane
Phospholipase A2 group VIF or
Patatin-like phospholipase
domain-containing protein 4
or GS2
iPLA2-VIF or iPLA2η PNPLA4 253 No Cytoplasm
Acidic
calcium-independent
PLA2 (aiPLA2)
Acidic calcium-independent
phospholipase A2
(or Peroxiredoxin-6)
aiPLA2 PRDX6 224 No Cytoplasm; lysosome
PAF acetylhydrolases
(PAF-AH)
Phospholipase A2 group VII or
Platelet-activating factor
acetylhydrolase or LDL-associated
phospholipase A2
PAF-AH or LpPLA2 PLA2G7 441 No Secreted
Phospholipase A2 group VIII
(multi-subunit enzymes formed
of alpha, beta and gamma subunits)
PAF-AH IB or PLA2-VIII PAFAH1B1/
PAFAH1B2/
PAFAH1B3
410/229/231 No Cytoplasm
Phospholipase A2 group VIIB PLA2-VIIB PAFAH2 392 No Cytoplasm
Lysosomal PLA2 Lysosomal phospholipase A2 or
Lysophospholipase 3 or
1-O-acylceramide synthase (ACS)
or LCAT-like
LPLA2 or LLPL LYPLA3 412 No Secreted; Lysosome
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induced by oleic acid, amarked increase of PLA2 activity in comparison
with control animals was observed. ALI was associated with surfactant
hydrolysis by sPLA2 as well as by a perturbation of surfactant ﬂuidity
caused by lyso-phospholipids. These result to an increase in airway
and capillary permeability and to altered alveolar epithelium barrier
function [55]. Separate research groups reported the increase of
sPLA2-IIA in BAL ﬂuid of ARDS patients [15,56] and these levels were
found to correlate positively with the severity of ARDS [57]. The levels
of sPLA2-IIA detected in BAL ﬂuid or cells were considered as a marker
for surfactant degradation and associated with ongoing alveolar
inﬂammation [58].
In ARDS patients, increased sPLA2-IIA levels were detected in BAL
ﬂuid, BAL cells and plasma [59]. Total PLA2 activity was inversely
correlated with PaO2/FIO2 ratio and positively with the mortality rate.
Patients with direct ARDS exhibited higher PLA2 activity compared
with patients with indirect ARDS. An interesting ﬁnding in this study
was that in ARDS patients, PLA2 activity was localized in the very small
surfactant aggregates; on the contrary, in control patients the enzyme
was localised predominately in the large surfactant aggregates. Very
small surfactant aggregates represent utilized-decomposed surfactant
with poor surface properties, providing an additional evidence for the
role of PLA2 in surfactant degradation in ALI and ARDS. Surfactant
phospholipid alterations in BAL ﬂuid from ARDS patients included an
increase in lyso-phospholipids, that was attributed to secreted
phospholipases A2 [11,60].
In BAL ﬂuid from ARDS patients, phosphatidylcholine (PC) was
markedly reduced, while lyso-PC, a product of PLA2 action on PC, was
increased. Interestingly, the level of PC was positively related with
survival of ARDS patients [15]. Elevated levels of plasma PLA2 were
also detected in patients with ARDS andMultiple-Organ Failure [61]. It
has been suggested that lung injury induced by intestinal ischemia–
reperfusion, as well as by acute hepatic deﬁciency appears to be
mediated by a mechanism that involves sPLA2-IIA activation [53,62].
Therefore, sPLA2-IIA seems to play an important role in the
development of acute lung injury since surfactant phospholipids are
major targets for the enzyme (Scheme 1–3).
2.1.3. sPLA2-IIA regulation
Arachidonic acid (AA) differentially affects the basal and lipopo-
lysaccharide-induced sPLA2-IIA expression: In unstimulated alveolar
macrophages from guinea pigs, AA directly inhibited sPLA2-IIA
expression via a process involving the impairment of NF-kB activation,
whereas in LPS-stimulated cells, AA effect is mediated via its oxidative
metabolism to the COX metabolites and the subsequent PPAR-γ
activation (Scheme 1–4). Alveolar macrophages represent the major
pulmonary source of sPLA2-IIA in LPS-induced ALI. Therefore, it is
suggested that PPAR-γ ligandsmay be useful in preventing ALI [46,63].
The transcription of sPLA2-IIA gene is induced by interleukin-1beta
(IL-1B), IL-6 and tumor necrosis factor (TNF-α), while it is partiallyScheme 1. Involvement of PLA2 isoforms in the evolution or prevention of acute lung injury (A
ones, the generation of eicosanoids and lipid mediators. In contrast, a protective role is ascrib
exhibit a direct hydrolytic action on lung surfactant (3, 5, 10, respectively). sPLA2-IIA or -IB c
through the MAPK cascade (1, 11). sPLA2-IIA expression is induced by COXmetabolites throug
Secretion of sPLA2-V leads to transcellular lipolytic action on inﬂammatory cells, liberating A
by proteolytic cleavage and under this form it is secreted from the cell (7). It could induce ALI
surfactant (10) and generation of lipid mediators (8). sPLA2-X could be internalized after b
surface PLA2R with high-afﬁnity inducing a variety of biological responses (11). Alternatively
the enzymes, moves to the plasmamembrane andmediates their internalisation and decomp
its translocation from the cytosol and nucleus to perinuclear membrane vesicles (14). A cr
generation, leading to ALI (15). The iPLA2β has been implicated in cellular processes such as
activation of Ca2+ inﬂux. iPLA2γ is suggested to participate in the regulation of sPLA2-IIA expr
regulation of surfactant phospholipids turnover (18) as well as in the protection of the lung a
XV may be a major enzyme of pulmonary surfactant phospholipid degradation (20). PAF-AH
is an autacoid molecule which acts via a cell surface receptor (PAFR) (21). However, PAF-A
catalyses the generation of lyso-phospholipids and fatty acid hydroperoxides (FA(OOH)) w
arrows: secretion; : recycling of damaged membranes.inhibited by dexamethasone [64]. Moreover, IL-1B acts in concert with
HMGB1 (amphoterin), an ubiquitous protein that plays various roles
in the nucleus, and activates the sPLA2-IIA genes, suggesting the
triggering of a regulatory pathway that may amplify inﬂammation
[65].
2.1.4. Other sPLA2 types
Regarding other sPLA2 isoforms discovered recently by sequence
homology identiﬁcation to sPLA2-IIA, the mammalian sPLA2-IIC, IID,
IIE, IIF, V, and X share similar three-dimensional structure to groups IB
and IIA. A wide proﬁle of sPLA2s have been found in primary human
lung parenchyma macrophages, including -IIA, -IID, -IIE, -IIF, -V, -X
and -XIIA. Some of them (-IIE, -IIF, -III, -V and -XIIB) were only
detected at the protein level. Regarding these isoforms, only sPLA2-IIA
was upregulated by LPS [66].
Alveolar macrophages express sPLA2-IID, -V and -X isoforms.
However, only sPLA2-V, and -X were found to hydrolyze efﬁciently
surfactant phospholipids in vitro, and this activity was inhibited by
surfactant protein A (Scheme 1–5, -9) [67]. In human bronchoepithe-
lial (BEAS-2B) and nasal epithelial (RPMI 2650) cells, TNF-a and IFN-γ
were able to induce gene expression of cPLA2-IVC and sPLA2-IID,
respectively. The above PLA2 types may thus be involved in cytokine-
induced inﬂammation in the respiratory tract [68].
Regarding sPLA2-V, it has a speciﬁc function related to phagocy-
tosis. In tissue macrophages, the enzyme is present in a prominent
juxtanuclear location in association with the Golgi network and the
recycling endosome. In response to zymosan stimulation, the enzyme
translocates to the phagosome. The ability of sPLA2-V to regulate
phagocytosis is speciﬁc and not shared with cPLA2α nor sPLA2-IIA [for
review, see ref. 69]. Moreover, it was shown that activated BEAS-2B
cells secrete sPLA2-V which exert transcellular lipolytic activity on
neighboring inﬂammatory cells (Scheme 1–6) [70]. The elevation of
sPLA2-V expression in mice lungs with severe inﬂammation can be
associated with an ongoing surfactant hydrolysis often observed in
lung dysfunction (Scheme 1–5) [71]. Finally, the involvement of
sPLA2-V in ALI has been demonstrated from experiments with speciﬁc
inhibition of the enzyme or gene targeted mice lacking sPLA2-V, in
which ALI was blocked and an attenuation of neutrophilic inﬂamma-
tion caused by LPS was observed [72].
sPLA2-X is found in an inactive form in the cytosol of alveolar type
II epithelial cells, under physiological conditions [73]. Its activation
under particular situations such as inﬂammation, requires cleavage of
an N-terminal propeptide (Scheme 1–7). sPLA2-X can regulate
alveolar type II epithelial cell functions by releasing fatty acids from
the cell membranes or by modulating the composition of cell
membrane phospholipids. Similar to sPLA2-V, it presents transcellular
lipolytic activity liberating AA from neighbouring and distal cells
(Scheme 1–8, –9) [73]. Although the enzyme can hydrolyse lung
surfactant monolayers, (Scheme 1–10), overexpressed sPLA2-X trans-
genic neonate mice displayed normal alveolar architecture andLI). Direct actions leading to ALI include the hydrolysis of lung surfactant, while indirect
ed to isoforms that mediate phospholipids remodeling: Secreted PLA2 types IIA, V, and X
an interact with speciﬁc receptors leading to genes expression and protein production
h PPAR-γ activation (4, 2). sPLA2-V has an autocrine or paracrine action on membranes.
A and other free fatty acids (6). During inﬂammation sPLA2-X is activated in the cytosol
through the liberation of free fatty acids frommembrane phospholipids, degradation of
inding with PLA2R and degraded (12). Secreted PLA2-IB, IIA and -X can bind to the cell
, a soluble, circulating form of sPLA2R acts as a negative regulator of sPLA2: This binds to
osition (13). cPLA2α requires submicromolar levels of intracellular Ca2+, which facilitate
oss-talk mechanism between cPLA2α and sPLA2-V leads to AA release and eicosanoid
phospholipids remodeling (16), eicosanoids formation, cell proliferation, apoptosis, and
ession (17) induced by inﬂammatory cytokines and endotoxin. aiPLA2 participates in the
gainst oxidative injury via reduction of peroxidized phospholipids (19). Lysosomal PLA2-
degrades platelet-activating factor and is considered as anti-inﬂammatory enzyme. PAF
H function could be also associated with the progression of inﬂammation because it
hich disrupt membrane integrity(22). Interrupted arrow: damage or degradation; Blue
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been shown to degrade in vitro platelet activating factor (PAF), a
potent inﬂammatory lipid mediator, when it is incorporated into large
unilamellar PC phospholipid vesicles [70,74].
2.1.5. sPLA2 receptor (PLA2R)
Although most of the biological effects of sPLA2s rely on the
hydrolysis of membrane phospholipids, the neurotoxicity and myo-
toxicity caused by certain sPLA2 isoforms in mammals are attributed
to speciﬁc binding of sPLA2 proteins to cell surface receptors (PLA2R).
Accordingly, two distinct types of receptors have been identiﬁed, the N
(neural)-type, expressed mainly in the brain, but a similar type was
found in other tissues as well, and the M (muscular)-type, expressed
in various mammalian tissues, including lung [75–77]. Later, the M-
type receptor, was cloned in various mammalian species including
humans and different secretory PLA2 types were investigated as
ligands [78,79].
A widely expressed PLA2R has been demonstrated in mice type II
alveolar epithelial cells and a subset of spleenic lymphocytes as well as
on the surface of polymorphonuclear neutrophils, and in human
alveolar macrophages, the ﬁrst line in lung host defence. In addition,
PLA2R is expressed in kidney, pancreas, amnion, choriodecidua and
placenta [80,81].
PLA2R is a type I transmembrane glycoproteinwith an approximate
molecular mass of 180 kDa. It belongs to the subgroup IV of a
particular C-type animal lectin family that includes the macrophage
mannose receptor, DEC in dendritic cells and endothelial cell lectin-
like lambda protein. These receptors mediate phagocytosis, pinocy-
tosis and antigen presentation [82].
Secreted PLA2-IB, IIA and -X can bind to the cell surface PLA2R with
high-afﬁnity in a Ca2+-independent manner and induce a variety of
biological responses. For example, binding of sPLA2-IB induces the
activation of the mitogen-activated protein kinase (MAPK) cascade
(Scheme 1–11) leading to cell proliferation, production of lipid
mediators and selective release of arachidonic acid in bone marrow-
derivedmast cells. In neutrophils, binding of sPLA2-IB can activate p38
MAPK, stimulates elastase release and cell adhesion. Another function
of PLA2R is associated to the clearance of sPLA2s, by internalization and
degradation (Scheme 1–12) [83].
Finally, a soluble form of PLA2R (sPLA2R) is constitutively present
in the circulation, acting as an endogenous inhibitor of sPLA2-IB, -IIA
and -X (Scheme 1–13). It is produced after cleavage by metallopro-
teinases of PLA2R and contains all the extracellular domains but lacks
the transmembrane and cytosolic regions [84].
PLA2R-deﬁcient mice had longer survival, were more resistant and
they exhibited lower LPS-induced cytokines in plasma compared with
the wild-type mice [85]. This reveals a potential role of the sPLA2-IB/
PLA2R in endotoxic shock and in the development of ARDS.
2.2. Cytosolic PLA2s (cPLA2s)
The cPLA2s are soluble cytoplasmic proteins with variable sizes,
(61–95 kDa), [86], which preferentially catalyze the hydrolysis of
arachidonic acid from the sn-2 position of phospholipids. The cPLA2-
IVA or cPLA2α, (gene PLA2G4A), was the ﬁrst to be identiﬁed. The
enzyme is also expressed in the lung among other tissues, it
additionally displays lysophospholipase activity and its catalytic
mechanism involves a Ser/Asp dyad [87].
cPLA2α participates in signal transduction. It requires physiologi-
cally relevant submicromolar levels of intracellular Ca2+, which
facilitate its translocation from the cytosol and nucleus to perinuclear
membrane vesicles (Scheme 1–14) [88]. Ca2+ binds to the C2 domain
and is not directly involved in the catalytic mechanism, in contrast to
sPLA2s [89]. The enzyme is activated by phosphorylation that is
catalysed by MAPK [90]. This conversion only stimulates the enzyme
activity, indicating that translocation and phosphorylation areindependent mechanisms of cPLA2 regulation. However, other
kinases, such as phosphoinositide 3-kinase (PI3K) in human eosino-
phils or SAPKs in platelets, seem to be involved in cPLA2-IVA phospho-
rylation and activation [91,92].
So far, ﬁve additional cPLA2 members based on sequence
homology have been identiﬁed in human: cPLA2-IVB or cPLA2β
(gene PLA2G4B), cPLA2-IVC or cPLA2γ (gene PLA2G4C), cPLA2-IVD or
cPLA2δ (gene PLA2G4D), cPLA2-IVE or cPLA2ɛ (gene PLA2G4E) and
cPLA2-IVF or cPLA2ζ (gene PLA2G4F).
The cPLA2-IVB has a much weaker activity than cPLA2-IVA. Human
lung epithelial cells (BEAS-2B) contain three RNA splice variants of
cPLA2β (β1, β2, and β3). cPLA2β3 is constitutively associated with
membrane in unstimulated BEAS-2B cells, localizing to mitochondria
and early endosomes. cPLA2β3 is removed from the membrane by
homogenizing BEAS-2B cells with excess EGTA, suggesting that Ca2+
plays a role in membrane binding [93].
cPLA2-IVC acts in a Ca2+-independent manner as it lacks the C2
domain and appears to be constitutively associated with membranes.
It is also expressed in lung epithelium [94]. Both cPLA2-IVB and cPLA2-
IVC show a preference for arachidonic acid at the sn-2 position of
phosphatidylcholine. cPLA2-IVC also possess lysophospholipase/
transacylation activities and it is though suggested that it may have
a protective role through clearance of lyso-phospholipids by its
transacylation [95].
cPLA2 is suggested to play a crucial role in the pathogenesis of
acute lung injury. Disruption of PLA2G4 gene signiﬁcantly reduced
acute lung injury caused by either endotoxemia or acid aspiration.
These observations indicated that PLA2G4 gene may mediate acute
lung injury, probably through the production of thromboxanes and
leukotrienes [96].
A Ca2+-dependent PLA2 was detected in high levels in BAL ﬂuid,
BAL cells and plasma of patients with ARDS. cPLA2might act indirectly,
through the synthesis of inﬂammatory lipid mediators, whereas the
co-localisation of cPLA2 and sPLA2 in BAL indicates that these enzymes
might act synergistically for the development of ALI.
2.2.1. Cross-talk between sPLA2 and cPLA2
It has been shown that distinct sPLA2s act in concert with cPLA2s in
regulating arachidonic acid metabolism and phospholipid turnover in
stimulated mammalian cells [97–100]. Stimulation of cells induces
cPLA2α and sPLA2-V activation and cross-talk that lead to AA release
and eicosanoid generation (Scheme 1–15). sPLA2-V contributes to AA
release and eicosanoid generation by inducing cPLA2α expression. In
addition, sPLA2-V can amplify the activity of cPLA2α through the
ampliﬁcation in phosphorylation by ERK. cPLA2αmay activate sPLA2-
V through the generation of LTB4 or 12/15 lipoxygenase products
[101]. Both enzymes may be additive in providing arachidonic acid for
eicosanoid generation [69].
sPLA2-V can be secreted and hydrolyse phosphatidylcholine at the
same or neighbouring cells, (Scheme 1–6). Apart from its catalytic
activity, additional functions of the enzyme are the regulation of
phagocytosis, foam cell formation, and antibacterial activities. sPLA2-V
regulates innate immune responses synergistically with cPLA2-α
downstream of TLR-2 [102].
2.3. Ca2+-independent PLA2 (iPLA2-VI)
Ca2+-independent PLA2s (iPLA2-VI) are cytosolic enzymes which
possess a serine in the active site similar to cPLA2s but are not speciﬁc
regarding to the fatty acid moiety. Different sizes of enzymes (from 53
to 146 kDa) with distinct tissue distribution, cellular localization and
enzyme activity can be produced by alternative splicing of the human
iPLA2 transcript of PLA2G6 gene [103–105]. The iPLA2-VIΑ (or iPLA2β)
isoform which is mostly studied, contains several ankyrin repeats
whichmediate protein–protein interactions in very diverse families of
proteins [106]. The ankyrin-iPLA2 sequence can function as a negative
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exhibit PLA2 activity only, whereas the others, VIC (or iPLA2δ), VID (or
iPLA2ɛ), VIE (or iPLA2ζ) and VIF (or iPLA2η), show additional
lysophospholipase, adiponutrin-like, triglyceride lipase and transacy-
lase activities, respectively [107,108]. The iPLA2γ is membrane-bound,
while iPLA2β is cytoplasmic [109].
The iPLA2β isoenzyme has been implicated in various cellular
processes such as phospholipids remodeling (Scheme 1–16), eicosa-
noid formation, cell proliferation, apoptosis, and activation of Ca2+
inﬂux [110,111].
The iPLA2 is moderately expressed in alveolar cells and macro-
phages, in A-549 bronchoepithelial cells and in normal and cancer
human lung tissue [112]. The isoforms iPLA2β and cPLA2α are
potential targets for anti-inﬂammatory strategies since they regulate
monocyte migration to the site of inﬂammation, with iPLA2β acting as
a critical regulator of the cellular compass [113]. Instead, iPLA2γ is
widely expressed across species and tissues and is suggested to play a
role in oxidant-induced cell injury [114] as well as to participate in the
regulation of sPLA2-IIA expression induced by inﬂammatory cytokines
and endotoxin (Scheme 1–17) [108].
The most powerful inhibitor of iPLA2 is BEL (bromoenol lactone).
The (S)- and (R)-enantiomers of BEL offer high speciﬁcity for the
differentiation between iPLA2β and iPLA2γ isoforms of the enzyme,
respectively. These enantiomers were applied to identify which
isoform was implicated in arginine vasopressin-induced arachidonic
acid release in A-10 smooth muscle cells [115].
2.3.1. Acidic Ca2+-independent PLA2 (aiPLA2)
Acidic, Ca2+-independent PLA2 is a 25-kDa multifunctional
enzyme of lysosomal origin, with dual phospholipase A2 and
peroxiredoxin 6 (or non-selenium glutathione peroxidase activities,
gene PRDX6). It has an optimum pH: 4.0, that differentiates it from
other iPLA2 enzymes [116,117]. The active sites comprise a catalytic
serine for phospholipase A2 activity and a catalytic Cys-47 which is
oxidized to Cys-SOH for the redox-activity (protein data bank number
1PRDX) [118]. Recent studies suggest that aiPLA2 activity is regulated
through phosphorylation in Thr-177 by MAPKs [119].
The enzyme has been isolated from rat lung and is insensitive to
pBPB and AACOCFs which inhibit other cytosolic phospholipases.
Hexadecyl-3-triﬂuoroethylglycero-sn-2-phosphomethanol (MJ33)
has been proposed as a speciﬁc inhibitor for aiPLA2 [120]. The activity
of aiPLA2 is inhibited by surfactant protein A through direct protein–
protein interaction with Prdx6 [121].
aiPLA2 is expressed primarily in lung among all the major organs.
It is found in the cytoplasm, cytoplasmic vesicles and lysosomes of
Clara cells of the conducting airways, type II epithelial cells and
alveolar macrophages [122]. Expression of aiPLA2 is elevated in
several lung diseases including lung cancer, mesothelioma and sar-
coidosis, although the mechanism for these alterations is not known
[123].
The unique properties of aiPLA2 disclose an important role for lung
cell function. The enzyme participates in the regulation of surfactant
phospholipids turnover in type II alveolar epithelial cells (Scheme 1–
18) as well as in the protection of the lung against oxidative injury by
reducing H2O2, using glutathione as an electron donor, short chain
organic fatty acids, and phospholipid hydroperoxides [124]. In
particular, it participates in the remodelling of phosphatidylcholine
to dipalmitoyl-phosphatidylcholine (DPPC) that maintains the physi-
cochemical properties of lung surfactant, being its major constituent.
aiPLA2 utilizes as substrate PC from the recycled small vesicular
formations of lung surfactant which are internalized and processed by
the lysosomes of pneumonocytes (Scheme 1–18) [125]. A recent
proteomic analysis of lamellar bodies isolated from rat lungs revealed
the presence of PRDX6 [126]. This ﬁnding strengthens the hypothesis
for an involvement of the enzyme on the degradation and recycling of
surfactant phospholipids.The role of the enzyme as an antioxidant was recently evaluated in
primary lung alveolar epithelial type II cells isolated from wild-type,
PRDX6−/−, or PRDX6 overexpressing transgenic mice. It was ob-
served that the protein facilitates the repair of damaged cell mem-
branes via reduction of peroxidized phospholipids (Scheme 1–19)
[127].
The protective role of aiPLA2 on lung function by promoting
surfactant DPPC biosynthesis and by exerting antioxidant activity
[125], consists a promising area for research.
2.4. Lysosomal PLA2 (PLA2-XV)
Lysosomal phospholipase A2 (PLA2-XV, gene LYPLA3) is a Ca2+-
independent enzyme with acyl-ceramide synthase (ACS), transacy-
lase and lysophospholipase (LLPL, LPLA2) activities. Ιt possesses a
sequence similarity to plasma lecithin:cholesterol acyltranferase
(LCAT) and initially it was thought to be associated with high-density
lipoprotein. Later-on it was found that LCAT and LPLA2 were encoded
by the same gene but in the case of LPLA2 it was posttranslationally
modiﬁed by both signal peptide cleavage and N-glycosylation. The
deglycosylated protein has a molecular mass of 45 kDa [128].
Human PLA2-XV shows the lipase motif with a catalytic triad of
ser/his/asp, several N-linked glycosylation sites and a pH optimum
at 4.5, suggesting that the enzyme is localised at lysosomes [129].
Rat and mice PLA2-XV is selectively expressed in alveolar macro-
phages but not in peritoneal macrophages, peripheral blood mono-
cytes, or other tissues [130]. It recognizes disaturated phosphatidyl-
choline as a substrate and has a broad positional speciﬁcity for the
acyl groups of both the 1st and 2nd position of phosphatidylcholine
and phosphatidylethanolamine.
LPLA2 is secreted from macrophages in response to phagocytotic
stimuli, while its re-incorporation into alveolar macrophages is
suggested to occur via a mannose or mannose phosphate receptor.
Deﬁciency of LPLA2 results in foam cells formation, surfactant lipid
accumulation and phospholipidosis, suggesting that PLA2-XV may be
amajor enzyme of pulmonary surfactant phospholipid degradation by
alveolar macrophages (Scheme 1–20). This was concluded from a
study with PLA2-XV knockout mice used as a model of pulmonary
alveolar proteinosis, a disorder of impaired surfactant catabolism.
Foam cell formation characterized by lamellar inclusion bodies of
alveolar and peritoneal macrophages was shown [131,132]. Further
evidence was provided by in vitro stimulation of mouse alveolar
macrophages with zymosan which induced LPLA2 release into the
medium, while LPLA2
(−/−) alveolar macrophages were characterized
by a marked accumulation of phosphatidylcholine and phosphatidy-
lethanolamine [133].
Lysosomal constituents are important for the inﬂammatory res-
ponse: The released lysosomal enzymes can cause damage in lung
tissue thus contributing in the pathogenesis of many diseases inclu-
ding complement activation-produced lung injury [134].
2.5. PAF acetylhydrolases
Phospholipases A2 with preference to short acyl chains at the sn-2
position of phospholipids are termed as platelet activating factor-
acetylhydrolases (PAF-AH). The name was derived from platelet-
activating factor, a potent inﬂammatory mediator, which was ﬁrstly
identiﬁed as the substrate of the enzyme. However, it has been also
shown that PAF-AH can readily hydrolyse short, oxidatively fragmen-
ted acyl-chains during oxidative stress [135,136]. From the three
distinct PAF-AH groups encountered in mammals, the ﬁrst includes a
secreted, single-subunit (45 kDa) isoform, the plasma PAF-AH or
lipoprotein-associated PLA2 (PLA2-VIIA) which is encoded by gene
PLA2G7. It degrades not only PAF but also phospholipids with short
(up to 9 carbon atoms) oxidatively fragmented acyl groups at the sn-2
position [137,138].
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his/asp catalytic aminoacids and its activity decreases with increasing
length of the fatty acyl-chain esteriﬁed at the sn-2 position of the
phospholipids [139]. It is ubiquitously expressed but the primary
source of the enzyme is macrophages. PAF-AH activity is also detected
in alveolar macrophages and epithelial type II cells [140].
The second group, cytosolic PAF-AHs IB (or PLA2-VIII) are multi-
subunit enzymes formed of 45 kDa (alpha), 30 kDa (beta) and 29 kDa
(gamma) subunits. Beta and gamma subunits possess catalytic acti-
vity, whereas the alpha subunit has regulatory function. Genes
PAFAH1B1, PAFAH1B2 and PAFAH1B3 encode the alpha, beta and
gamma subunit, respectively. The third group is a cytoplasmic 40 kDa
single-subunit protein designated as PLA2-VIIB which is a serine-
dependent phospholipase A2 encoded by gene PAFAH2 and is broadly
expressed in different tissues [141].
Among the inﬂammatory mediators which are involved in the
pathogenesis of ARDS, platelet activating factor (PAF) has received
increased attention in recent years. PAF is an autacoid molecule which
acts via a cell surface receptor (PAFR) (Scheme 1–21) and is con-
sidered as one of the most potent pro-inﬂammatory mediators. PAF is
detected in high levels in lungs and plasma of animal models with
ARDS, as well as in bronchoalveolar lavage ﬂuid (BALF) of ARDS
patients [15,142]. PAF signiﬁcantly activates neutrophils, enhances the
release of various cytokines and chemokines and increases vascular
permeability during the process of ARDS [143]. The important role of
PAF in ARDS was conﬁrmed in a study of lung injury caused by HCl
aspiration: overexpression of PAFR gene in transgenic mice enhanced
lung injury, pulmonary oedema and deterioration of gas exchange,
while mice carrying a targeted disruption of the PAFR gene presented
signiﬁcantly less expression of all the aspects of the injury [144].
Moreover, PAF-AH activity levels were elevated in BAL ﬂuid, plasma
and serum from patients with ARDS [145]. Of interest, in ARDS
patients, PAF-AH activitywas distributedmainly in the large surfactant
aggregates, whereas in patients without ARDS the activity was loca-
lised in the very small surfactant aggregates indicating that this topo-
logy could be correlated with a role and function of PAF-AH to
inactivate PAF and oxidized phospholipids. In a recent study, PAF-AH
expression was demonstrated in alveolar macrophages and lung
epithelial cells of animal models with oleic acid-induced ALI, suggest-
ing a local production and secretion by alveolar macrophages [146].
Due to their substrate preference, an anti-inﬂammatory role has
been ascribed to PAF-AHs. However, controversial views suggest that
their function could be also associated with the progression of
inﬂammation because it catalyses the generation of lyso-phospholi-
pids and fatty acid hydroperoxides (ROS). Lyso-phospholipids are able
to induce severe alveolar epithelial injurywhile lyso-PC has a dramatic
and dose-dependent tissue-damaging effect [147]. Lung tissue is a
major target of ROS which induce acute lung injury [148] (Scheme 1–
22). The lower levels of PAF-AH activity measured in plasma in severe
sepsis, prompted a treatment with recombinant PAF-AH but this did
not reduce the incidence of ARDS in patients with severe sepsis
[149,150]. Finally, recent clinical studies proposed this enzyme as a risk
marker or risk factor of coronary heart disease [151–153].
2.6. Inhibitors of PLA2
2.6.1. sPLA2 inhibitors
Chemical inhibitors are used as tools for the identiﬁcation of PLA2
isotypes in biological samples and the investigation of PLA2 properties
and pathophysiological role in various inﬂammatory diseases. Many
different classes of compounds have been found to inhibit sPLA2s at
the active site. Today, speciﬁc inhibitors are available for most of the
sPLA2s subtypes [154,155] and some of them have been used in studies
for the treatment of ALI/ARDS.
Indole derivatives appeared to be the most potent mammalian
sPLA2 inhibitors. Indoxam, LY311727 and Me-indoxam are potentsPLA2 inhibitors. A number of studies in ARDS in which LY311727 was
used as an inhibitor for sPLA2-IIA have also been published [46,156–
158]. However, indoxamwas suggested to interfere with sPLA2-IB and
-X binding to its cell surface receptor [159]. Therefore, inhibition of
cellular responses by this type of inhibitors is not always associated to
the inhibition of enzymic activity of the sPLA2. Me-Indoxam has the
highest potency among these inhibitors [160] but has the disadvan-
tage that it is not cell-permeable [161]. Recently, it has been proposed
that substituted indole and indolizine sPLA2 inhibitors may be useful
in the study of the role of various mammalian sPLA2s in cellular and
whole animal responses [155].
Prophylactic treatment with the human sPLA2-IIA inhibitor S-
5920/LY315920Na signiﬁcantly ameliorated oleic acid-induced ALI in
rabbits, as evidenced by signiﬁcant improvement of hypoxemia and
reduced compliance, the prevention of pulmonary oedema, and a
decrease in the leakage of proteins into alveolar airspaces [61]. More-
over, S-5920/LY315920Na completely prevented intestinal ischemia/
reperfusion-induced lung capillary–alveolar permeability [52] and
attenuated acute lung injury in an animal model of ARDS via surfac-
tant protection [162,163].
Another class of inhibitors tested very recently are those derived
from YM-26734 and it was observed that nanomolar concentrations
inhibited human, mouse and rat sPLA2-IIA and sPLA2-V but not sPLA2-
X. These hydrophobic, cell-permeable inhibitors may be useful for
mouse and rat cellular studies of sPLA2 function [164].
The effort on inhibitors research is to optimize their selectivity
among the sPLA2 groups, for the implementation on treatment of
ARDS patients.
2.6.2. Endogenous inhibitors of sPLA2
Surfactant-associated SP-A can act as an endogenous inhibitor of
sPLA2-IIA and -X, but not of -V, by interacting with their carbohydrate
recognition domain. It may exert protection bymaintaining surfactant
integrity during lung injury. This was concluded from in vivo
experiments where sPLA2-IIA-induced more pronounced ARDS in
SP-A deﬁcient than in wild-type mice. In vitro, SP-A in surfactant
preparations inhibits sPLA2-IIA-induced surfactant hydrolysis in a
dose-dependent manner [67]. Experiments with puriﬁed SP-A con-
ﬁrmed the inhibitory properties against sPLA2-IIA. SP-A, is a member
of the C-type lectin superfamily that contains a COOH-terminal
carbohydrate recognition domain and plays an important role in
pulmonary host defence by inhibiting inﬂammation during lung
infection. Decreased SP-A levels in BALF are observed in patients with
ARDS or at risk for developing ARDS [165]. Increased sPLA2 activity is
associated with decreased SP-A, while surfactant causes a downregu-
lation of sPLA2-IIA expression in alveolar macrophages of an
experimental model of ALI [166]. In vivo administration of a semi-
synthetic surfactant in an animal model of ALI reversed the increase in
sPLA2-IIA expression in lung tissues caused by intratracheal instilla-
tion of LPS [167].
Phospholipid components of surfactant also play a role in the
inhibition of sPLA2-II expression. Among surfactant phospholipids,
phosphatidylglycerol, which is known to inhibit PAF [168], was the
most effective in inhibiting the expression of sPLA2-II in alveolar
macrophages [169].
2.6.3. cPLA2 inhibitors
There are several commonly used inhibitors for cPLA2-IVA
including methyl arachidonyl ﬂuorophosphonate (MAFP) [170],
arachidonyl triﬂuoromethylketone (ATFK or AACOCF3) and pyrro-
phenone [171]. In addition to cPLA2-IVA, MAFP also irreversibly
inhibits iPLA2-VI [172], and PAF-AH activity [173]. ATFK also inhibits
iPLA2-VI [174] and cyclooxygenase [175].
ML3176, which is also characterized as a speciﬁc inhibitor for
cytosolic PLA2 [176], showed to inhibit partially the overall Ca2+-
dependent PLA2 activity detected in BAL ﬂuid, BAL cells and plasma of
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inﬂammation in ARDS.
Pharmacological interventions for cPLA2, by administering ATFK,
showed a signiﬁcant attenuation in lung injury in a sepsis murine
model [177]. Furthermore, ATFK reduced cPLA2 and sPLA2 activity,
thromboxane and leukotriene formation, as well as the expression of
PAF receptor in an isolated rat model of lung ischemia–reperfusion
injury [178]. Pyrrolidine1 and AZ-1 also tested as inhibitors of cPLA2-α
in stimulated primary cultures of human lung macrophages caused a
reduction in AA release and PAF production, suggesting their possible
application in the treatment of acute lung injury.
2.6.4. PAF-AHs inhibitors
PAF-AHs are inhibited at the catalytic subunit by organopho-
sphorus compounds. Themost common chemical inhibitors of plasma
PAF-AH in vitro are PMSF and DFP, active in mM concentrations
[179,180]. Plasma PAF-AH is also inhibited by the esterase inhibitors
MAFP, its linoleoyl homolog, and 4-(2-Aminoethyl)-benzenesulfonyl
ﬂuoride hydrochloride (Pefabloc) [181]. Highly potent inhibitors of
PAF-AH are also obtained with sub-nanomolar potency. Among them,
darapladib (SB-480848), demonstrated the best in vitro and in vivo
proﬁles and nowadays is being tested in clinical trials of coronary
heart disease [182].
2.6.5. Glucocorticoids
Glucocorticoids (GCs) are known for their inhibitory effect on PLA2
expression, while glucocorticoid receptor (GR) activation correlates
negatively with sPLA2 and cPLA2 expression. Due to their lipophilic
nature, GCs pass freely through the cell membranes and then can bind
to glucocorticoid receptor α (GRα) which is located in the cytosol in a
resting state. Ligand binding induces a conformational change of the
receptor which is released from its chaperones and translocates to the
nucleus. The beneﬁcial effects of activated GR are thought to be due to
both a negative modulation of pro-inﬂammatory cytokines and to the
positive regulation of anti-inﬂammatory genes. GCs inhibit the
transcription factors NF-kB, activator protein-1 (AP-1) or cAMP
response element-binding protein (CREB). The transcription factor
NF-kB activates genes encoding numerous of inﬂammatory molecules
such as PLA2, interleukins etc. [183,184].
GCs have multiple effects on fetal development. They play a role in
promoting maturation of the lung and pulmonary surfactant. Mice
with homozygous disruptions in the corticotropin-releasing hormone
gene die at birth due to pulmonary immaturity. GCs enhance surfac-
tant production by inducing enzymes of the “deacylation–reacylation
pathway” involved in palmitate incorporation into phosphatidyl-
choline thereby contributing to the acceleration of dipalmitoyl-
phosphatidylcholine biosynthesis [185]. The antenatal corticosteroid
administration has reduced the morbidity associated with preterm
birth [186].
Regarding inﬂammation, GCs inﬂuence non-speciﬁcally all types of
inﬂammatory events. They induce the lipocortin-1 (annexin-1)
synthesis, which then binds to cell membranes, preventing PLA2
contact with its substrate. This leads to diminished eicosanoid pro-
duction. Cyclooxygenase expression, (both COX-1 and COX-2), is also
suppressed [187]. Corticosteroids markedly reduce COX2 activity in
human airway epithelial cells in vitro, exhibiting little effect on COX1,
cPLA2-IV, or iPLA2-VI [188]. A major mechanism of GC action in
preventing prostaglandin release is proposed to occur through the
suppression of cPLA2 and COX-2mRNA levels in human epithelial cells
[189].
A variety of synthetic GCs, some far more potent than cortisol, have
been created for therapeutic use [190]. Pretreatment of Wistar rats
with indomethacin and dexamethazone diminishes the toxic effect of
phospholipase A2 administration in the lungs [191]. Furthermore, it is
demonstrated that GCs suppress the enhanced tissue expression of
the PLA2-IIA gene in endotoxic shock rat models [192].In endotoxemic guinea pigs that underwent repeated administra-
tion of dexamethasone during 3 days before the LPS challenge,
dexamethasone showed to prevent both early events such as the
macrophage priming and the TNF-alpha appearance and late events
such as extracellular PLA2 release and neutrophils recruitment [193].
In a sheep lung injury model induced by Escherichia coli endotoxin,
a reduced GR binding capacity was observed that was associated with
an elevation of cortisol levels in plasma and an increase in PLA2
activity. It was suggested that the glucocorticoid hypofunction acce-
lerates the pathologic response of acute lung injury and indicates an
implication of PLA2 in lung damage [194].
In conclusion, GCs exert inhibitory effects in several stages of the
inﬂammatory cascade, includingPLA2 attenuation. Therefore, they could
be a rational choice for treatment of acute lung injury. However, clinical
outcomes in trials on the role of GCs in ARDS treatmentwere ambiguous
[195,196]. The reduced response toGCswhich is observed inunresolving
ARDS maybe due to reduced GR binding to cortisol and/or GRα
overexpression which is recently reported to occur during ALI [197].
3. PLA2s as targets for ARDS treatment
PLA2s are obviously taking part in ARDS pathogenesis directly or
via the generation of lipid mediators. Therefore, the inhibition of PLA2
activities or modulation of PLA2s production and secretion constitutes
a promising therapeutic goal. However, it is not clearly understood
which isoform(s) are the suitable targets. Particular PLA2s exert anti-
inﬂammatory properties, while the bactericidal properties of sPLA2-
IIA place the function of sPLA2-IIA in another perspective [198].
Therefore, the systemic, non-selective inhibition of PLA2s might add to
adverse outcomes and the complete elimination of certain isoforms,
such as iPLA2 and cPLA2 with an essential role in cellular phospho-
lipids metabolism, might be detrimental.
The speciﬁc functions of PLA2 isoforms appear to be tissue-, organ-
and disease-speciﬁc. The treatment with PLA2 inhibitors should take
into account their organ speciﬁcity and the ability of some of them to
act as homeostatic and anti-inﬂammatory agents [199]. Issues such as
solubility, timing and dose, systemic or local administration should be
addressed. It has been suggested that a preferable strategy for con-
trolling inﬂammatory lipid mediator production is to protect the cells
from sPLA2, using cell-impermeable sPLA2 inhibitors that would not
interfere with the vital intracellular phospholipid metabolism [200].
Speciﬁc inhibition of cPLA2-IVA, sPLA2-IIA or sPLA2-V, may present
a valuable advance in treating ARDS since these enzymes play
essential role in the onset and development of the syndrome. How-
ever, continuous 7-days infusion of LY315920NA/S-5920, a selective
inhibitor of sPLA2-IIA, had no beneﬁcial effect on mortality among
severe sepsis patients with at least two organ failures [201].
Modulation of PLA2 secretion, production or activation could be
another therapeutic approach in ARDS prevention and treatment.
Therefore, the modulation of PLA2 with preconditioning, for example
ischemic preconditioning, could limit the use of potentially harmful
inhibitors of PLA2. Ischemic preconditioning refers to an adaptational
response to ischemia reperfusion injury that allows protection of
brieﬂy ischemic tissues against the harmful effects of subsequent,
prolonged ischemia (risk factor for ARDS). In a recent study we tested
the effect of ischemic preconditioning on the intestinal ischemia–
reperfusion-induced ARDS in rats, with particular focus on PLA2s. It
was observed that PLA2, as well PAF-AH were signiﬁcantly lower in
ischemic preconditioned rats. The PLA2s decrease was associated with
signiﬁcant reduction of neutrophils in BAL ﬂuid and lung tissue
inﬁltration. These results suggest that intestinal preconditioning pro-
tects intestinal ischemia–reperfusion-induced lung injury by mod-
ulating PLA2s secretion [202].
Corticosteroids, anti-inﬂammatory agents and non-selective inhi-
bitors of PLA2 have been used in the prevention of acute respiratory
distress syndrome in critically ill adults as well as for the treatment of
950 E. Kitsiouli et al. / Biochimica et Biophysica Acta 1792 (2009) 941–953established ARDS. However, a deﬁnitive beneﬁcial effect has not been
established: a resent systematic review failed to show a convincing
treatment effect of steroids in ARDS, although a trend of reduction in
odds of mortality was found when steroids were given after the onset
of ARDS. On the contrary, preventive steroid therapy in critically ill
patients was associated with detrimental effects on the incidence of
ARDS and subsequent mortality. Although steroids did not increase
the overall infection risk, a dose-dependent effect of steroid therapy
on infection rates seemed to exist. Furthermore, the optimal dose,
timing, and duration of steroid therapy have not been accurately
deﬁned [195].
4. Conclusion
Several PLA2s are involved inpathogenesis of inﬂammation inARDS
either directly or indirectly through the production of biologically
active molecules, however, some PLA2s may have anti-inﬂammatory
properties and others are responsible for surfactant production. All
these clearly make a therapeutic target in ARDS based in PLA2s inhi-
bition, a difﬁcult and complex approach.
Elucidation of the biological roles of each group of PLA2s in every
state of ARDS should be of great value for the development of subtype-
speciﬁc inhibitors as therapeutic agents.
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